| 000 | 00944 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250518054553.0 | ||
| 264 | 0 | _c20200204 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1179-1950 | ||
| 024 | 7 |
_a10.1007/s40265-019-01187-w _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDhillon, Sohita | |
| 245 | 0 | 0 |
_aBremelanotide: First Approval. _h[electronic resource] |
| 260 |
_bDrugs _cSep 2019 |
||
| 300 |
_a1599-1606 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xtherapeutic use |
| 650 | 0 | 4 |
_aSexual Dysfunctions, Psychological _xdrug therapy |
| 650 | 0 | 4 |
_aalpha-MSH _xmetabolism |
| 700 | 1 | _aKeam, Susan J | |
| 773 | 0 |
_tDrugs _gvol. 79 _gno. 14 _gp. 1599-1606 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40265-019-01187-w _zAvailable from publisher's website |
| 999 |
_c30021581 _d30021581 |
||